S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies

Wagner, Nikolaus B.; Forschner, Andrea; Leiter, Ulrike; Garbe, Claus; Eigentler, Thomas K.

dc.contributor.author	Wagner, Nikolaus B.
dc.contributor.author	Forschner, Andrea Lydia
dc.contributor.author	Leiter-Stöppke, Ulrike
dc.contributor.author	Garbe, Claus
dc.contributor.author	Eigentler, Thomas
dc.date.accessioned	2019-07-12T10:32:27Z
dc.date.available	2019-07-12T10:32:27Z
dc.date.issued	2018
dc.identifier.issn	1532-1827
dc.identifier.uri	http://hdl.handle.net/10900/90438
dc.language.iso	en	de_DE
dc.publisher	Nature Publishing Group	de_DE
dc.relation.uri	http://dx.doi.org/10.1038/s41416-018-0167-x	de_DE
dc.subject.ddc	610	de_DE
dc.title	S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies	de_DE
dc.type	Article	de_DE
utue.quellen.id	20190321153956_01732
utue.publikation.seiten	339-346	de_DE
utue.personen.roh	Wagner, Nikolaus B.
utue.personen.roh	Forschner, Andrea
utue.personen.roh	Leiter, Ulrike
utue.personen.roh	Garbe, Claus
utue.personen.roh	Eigentler, Thomas K.
dcterms.isPartOf.ZSTitelID	British Journal of Cancer	de_DE
dcterms.isPartOf.ZS-Issue	3	de_DE
dcterms.isPartOf.ZS-Volume	119	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE